Compare Abbott Laboratories (ABT) vs MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs MicroSectors FANG and Innovation 3X Leveraged ETN — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while MicroSectors FANG and Innovation 3X Leveraged ETN trades at $27.36. The key difference: Abbott Laboratories pays a 2.63% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | FNGU | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $136.62 | $36.15 |
52-Week Low | $82.57 | $13.73 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
FNGU is a leveraged exchange-traded note tracking the FANG+ Index, currently trading at $27.39, up 3.4% over the past day. Technical indicators show a bullish trend with strong moving average signals, though oscillators are neutral and short-term RSI suggests caution. Recent news highlights extreme volatility, with a 16% single-session drop reported on June 5, 2026, underscoring the risks of its 3x leverage structure.
The outlook for FNGU is highly speculative, offering amplified exposure to major tech stocks but carrying significant decay and volatility risks. Investment opportunity exists for aggressive traders betting on sustained tech sector strength, while the primary risk is rapid capital erosion during market downturns or flat periods, as evidenced by recent performance gaps versus the underlying index.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →
